Monitor upcoming FDA feedback on trial design and the search for a new CFO, as leadership transition could impact execution despite promising clinical data.
Price Chart
Executive Summary
Fulcrum Therapeutics terminated a license agreement for its Diamond-Blackfan anemia program, reported Q1 2026 earnings with a net loss per share of $-0.25 (in line with expectations), and announced the retirement of its CFO while appointing a new board member. Despite positive clinical data for its sickle cell disease drug pociredir and a cash runway into 2029, the termination of a development program and CFO retirement create mixed sentiment.
Key Financial Metrics
Key Facts
- Terminated license agreement for Diamond-Blackfan anemia program with CAMP4 Therapeutics
- Net loss per share of $-0.25 for Q1 2026, in line with consensus estimate of $-0.30
- Cash position decreased to $333.3 million from $352.3 million in Q4 2025
- CFO Alan Musso plans to retire later this year
- Appointed Josh Lehrer, M.D., to the Board of Directors
Financial Impact
Net loss of $18.9 million for Q1 2026, cash runway into 2029
Risk Factors
- Termination of Diamond-Blackfan anemia program eliminates potential future revenue stream
- CFO retirement creates leadership uncertainty during a critical development phase
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-178806 |
| Document: fulc-20260423.htm | 0001193125-26-178806 |
| Document: 0001193125-26-178806-index-headers.html | 0001193125-26-178806 |
| Document: 0001193125-26-178806-index.html | 0001193125-26-178806 |
| Document: 0001193125-26-178806.txt | 0001193125-26-178806 |
| 8-K Data (Synthetic) | 0001193125-26-178806 |
Track record
23 reports on FULC
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers